Free Trial

Enveric Biosciences Q3 2023 Earnings Report

Enveric Biosciences logo
$0.34 -0.02 (-4.66%)
As of 04:00 PM Eastern

Enveric Biosciences EPS Results

Actual EPS
-$1.30
Consensus EPS
-$1.93
Beat/Miss
Beat by +$0.63
One Year Ago EPS
N/A

Enveric Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Enveric Biosciences Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Enveric Biosciences Earnings Headlines

Tesla Shares Soar After Trump Win (Act Now)
Are you ready to see why Tesla might be the biggest opportunity on the market today? Right now, Tesla stock is at a critical juncture, and Lance believes it’s primed for explosive growth. That’s why he’s giving away his eBook, The Bullish Case for Tesla, for FREE—but only for a limited time.
Enveric in out-licensing deal with MycoMedica Life for EB-002
See More Enveric Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enveric Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enveric Biosciences and other key companies, straight to your email.

About Enveric Biosciences

Enveric Biosciences (NASDAQ:ENVB), a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

View Enveric Biosciences Profile

More Earnings Resources from MarketBeat